Results 81 to 90 of about 4,690 (200)

Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis [PDF]

Canadian Journal of Ophthalmology, 2022
Matthew J. Miller, Rod Foroozan
openaire   +2 more sources

Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis

medRxiv
Background: There is a paucity of knowledge on the longer-term effects of CF transmembrane conductance regulator (CFTR) modulator therapies upon the gut microbiome and associated outcomes.
R. Marsh, Claudio dos Santos, Alexander Yule, N. Dellschaft, Caroline L Hoad, C. Ng, G. Major, Alan R. Smyth, D. Rivett, C. van der Gast   +9 more
semanticscholar   +1 more source

Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials

SAGE Open Medicine
Objective: This study aimed to conduct a systematic review and meta-analysis of randomized controlled trials to evaluate the effects of elexacaftor–tezacaftor–ivacaftor (ELX-TEZ-IVA) on patients with cystic fibrosis (CF). Methods: A systematic search was
Rong He, Fei Lin, Zehui Deng, Bin Yu
doaj   +1 more source

Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
BACKGROUND The potential effects of the very effective cystic fibrosis triple combination drug, Elexacaftor/Tezacaftor/Ivacaftor (ETI) in pregnancy on prenatal development of offspring remain largely unknown.
Danni Li, Yimin Zhu, M. Donnelley, David Parsons, M. Habgood, E. Schneider-Futschik   +5 more
semanticscholar   +1 more source

Plasma levels of chemokines decrease during elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis

Heliyon
Background: Cystic fibrosis (CF) is associated with dysregulated immune responses, exaggerated inflammation and chronic infection. CF transmembrane conductance regulator (CFTR) modulator therapies directly target the underlying protein defects and ...
Dirk Westhölter, Johannes Pipping, Jonas Raspe, Mona Schmitz, Sivagurunathan Sutharsan, Svenja Straßburg, Matthias Welsner, Christian Taube, Sebastian Reuter   +8 more
doaj   +1 more source

INITIATION OF ELEXACAFTOR-TEZACAFTOR-IVACAFTOR LEADING TO LUNG TRANSPLANTATION [PDF]

Chest, 2020
Travis Homan, Stephanie Link, Christopher Barrios   +2 more
openaire   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Quality of Life in Children With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Kümmerli S, Elviro CF, Regamey N, Mornand A, Faouzi M, Rochat I, Blanchon S.   +6 more
europepmc   +1 more source

Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. [PDF]

Ann Am Thorac Soc
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM, PROMISE Study Group .   +15 more
europepmc   +1 more source

Editorial: Real-world experience with CFTR modulator therapy

Frontiers in Pharmacology, 2023
Burkhard Tümmler, Burkhard Tümmler, Pierre-Régis Burgel, Pierre-Régis Burgel   +3 more
doaj   +1 more source

The impact of elexacaftor-tezacaftor-ivacaftor on cardiometabolic risk factors: a systematic review. [PDF]

Eur Respir Rev
Girouard H, Jaber F, Gharib J, Boudreau V, Alexandre-Heymann L, Coriati A.   +5 more
europepmc   +1 more source